Phase II evaluation of menogaril in pati
✍
Harry J. Long; Harry S. Wieand; John F. Foley; Robert D. Niedringhaus; John A. L
📂
Article
📅
1991
🏛
Springer US
🌐
English
⚖ 170 KB
Fourteen patients with advanced/recurrent squamous cell carcinoma of the uterine cervix received menogaril, 200 mg/m 2 by one hour intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was less than two months and median survival was seven mo